Capture.JPG (55.79 kB)

Sodium Oligomannate: First Approval

Download (55.79 kB)
online resource
posted on 09.02.2020 by Yahiya Y. Syed
Compliance with Ethical Standards

Funding: The preparation of this review was not supported by any external funding.

Conflict of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Syed is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found here

Abstract
Sodium oligomannate (九期一®; GV-971) is a marine algae-derived oral oligosaccharide being developed by Shanghai Green Valley Pharmaceuticals for the treatment of Alzheimer’s disease (AD). Sodium oligomannate received its first approval in November 2019 in China for the treatment of mild to moderate AD to improve cognitive function. This article summarizes the milestones in the development of sodium oligomannate leading to this first approval for AD.

© Springer Nature Switzerland AG 2020

History

Exports

Read the peer-reviewed publication

Logo branding

Categories

Exports